Director/PDMR Shareholding
Updated : 10:30
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
10 June 2020
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 8 June 2020, Mr Jurgens Myburgh, Group Chief Financial Officer of Mediclinic International plc, acquired 7 500 shares in the Company at ZAR 63.94 per share. This purchase has been made in accordance with the Company's Remuneration Policy, whereby Mr Myburgh is required to maintain a minimum shareholding of 200% of his annual base compensation and until he has met that target, to purchase shares in the Company with 50% of the post-tax proceeds received from the deferred portion of awards made under the Short Term Incentive scheme and settled in cash. Mr Myburgh now owns a total of 90 500 shares in Mediclinic International plc.
The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
1. | Details of PDMR / persons closely associated with them ("PCA")
| |||||||||||||||||||||||||
a) | Name | Mr Petrus Jurgens Myburgh
| ||||||||||||||||||||||||
2. | Reason for the notification
| |||||||||||||||||||||||||
a) | Position / status | Group Chief Financial Officer of the Company
| ||||||||||||||||||||||||
b) | Initial notification / amendment | Initial Notification
| ||||||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||||||||||||||||
a) | Name | Mediclinic International plc
| ||||||||||||||||||||||||
b) | LEI | 2138002S5BSBIZTD5I60
| ||||||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||||||||||||||||
a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||||||||||||||||||||||
b) | Nature of the transaction | Purchase of shares
| ||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||
d) | Aggregated information
Aggregated volume
Price |
7 500
ZAR 63.94 per share
| ||||||||||||||||||||||||
e) | Date of the transaction | 8 June 2020; 09:26 UTC
| ||||||||||||||||||||||||
f) | Place of the transaction | Johannesburg Stock Exchange
| ||||||||||||||||||||||||
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 1 June 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, three day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.
The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9548
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.